Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera
Study Treatment
Phase 1:
Phase 2:
Key Study Criteria*
Inclusion:
Exclusion:
*Additional criteria apply
Primary Outcome Measures for Phase 1
Primary:
Secondary:
Primary Outcome Measures for Phase 2
Study Duration
Please use the form below to contact us if you would like more information about the Polycythemia Vera clinical study.